Oncodesign Precision Medicine: Volatile Dip, Still a Strong Long‑Term Opportunity
Oncodesign Precision Medicine dips 3% but remains on a 31% YTD gain—investors eye future milestones for a potential rebound to €0.92.
- ONCODESIGN PRECISION MEDICIN
- France
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read